Cigna PBM Express Scripts Excludes Humira in Favor of Biosimilars

Monday, 26 August 2024, 19:03

Cigna PBM Express Scripts is making waves by excluding Humira from many formularies. This move prioritizes cheaper biosimilar options effective in 2025.
Seeking Alpha
Cigna PBM Express Scripts Excludes Humira in Favor of Biosimilars

Cigna PBM Express Scripts Takes Action

Cigna PBM Express Scripts has announced a significant decision to remove Humira from numerous formularies. As a potent rheumatoid arthritis medication, AbbVie’s Humira has been a mainstay for many patients. However, in a bid to lower costs, Cigna is leaning towards introducing cheaper biosimilar versions of the drug by 2025.

The Financial Implications

This decision may lead to profound changes in the pharmaceutical landscape, impacting both patients and drug manufacturers. Lowering costs is a primary focus for healthcare providers, and this strategy might increase the adoption of biosimilars, further shifting market dynamics.

Industry Repercussions

As biosimilars gain traction, the competition may spur innovation and drive down prices across the sector. Cigna’s move reflects a growing trend among pharmaceutical benefits managers to enhance cost-efficiency.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe